Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003556 | 1.00 | TRPV1 (0.36) | TRPV1NOD1NOD2KMOTRPA1 | |
| SCHEMBL14003555 | 0.94 | TRPV1 (0.37) | TRPV1NOD1NOD2KMOTRPA1 | |
| SCHEMBL14003553 | 0.94 | TRPV1 (0.37) | TRPV1NOD1NOD2KMOTRPA1 | |
| SCHEMBL14028383 | 0.90 | NOD1 (0.40) | TRPV1NOD1NOD2KMOTRPA1 | |
| SCHEMBL14028385 | 0.90 | NOD1 (0.40) | TRPV1NOD1NOD2KMOTRPA1 | |
| SCHEMBL14003548 | 0.87 | KMO (0.39) | NOD1NOD2KMOTRPA1 | |
| SCHEMBL14003547 | 0.87 | KMO (0.39) | NOD1NOD2KMOTRPA1 | |
| SCHEMBL14003551 | 0.85 | KMO (0.38) | NOD1NOD2KMOTRPA1 | |
| SCHEMBL14003552 | 0.85 | KMO (0.38) | NOD1NOD2KMOTRPA1 | |
| SCHEMBL14003543 | 0.85 | KMO (0.40) | TRPV1NOD1NOD2KMOTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | IFNG, IL2, LY96 | TRPV1 1498/4885NOD1 130/4885NOD2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.